KT-4000 series

N/A

Report date: 2025/06/11 11:14:29
NME

Base Information

Drug NameKT-4000 series
Drug Alias NameDNA-damaging DDR inhibitors (Rakovina Therapeutics/University of British Columbia)DDR inhibitors (Rakovina Therapeutics/University of British Columbia)KT-4259KT-4503
ClassificationSmall molecules
Mechanisms of ActionDiscoidin domain receptors inhibitorsAnticancer protein kinase inhibitorsApoptosis stimulants
TargetsDiscoidin domain receptors
Therapy Area/IndicationsProstatic NeoplasmsOvarian NeoplasmsTriple Negative Breast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNewGLab Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesRakovina Therapeutics IncThe University Of British Columbia
Inactive CompaniesNewGLab Therapeutics
Active IndicationsProstatic NeoplasmsOvarian NeoplasmsTriple Negative Breast Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A